Today is World Cancer Day! Help us to raise awareness for Cancer and the importance of cancer education - become a CERI Golden Hearts member today!
#WorldCancerDay #Cancer #patienteducation #publiceducation #cancereducation #cancerawareness #canceredinstitute
Read the scientific article entitled Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells here.
To learn more about Acute Lymphoblastic Leukemia (ALL), read our article here.
#leukemia #ALL #AcuteLymphoblasticLeukemia #CAR #CARTCells #immunesystem #geneengineering #TALEN #Crispr #geneediting #universalTcells #universalimmunecells #childhoodleukemia #cchildhoodcancer #universitycollegelondon #cancerresearch #cancertreatment #cancer #cancereducation #patientenducation #publiceducation #canceredintitute
Researchers from Ruhr-University in Bochum, Germany, treated human samples of breast cancer cells with Capsaicin to dissect its ability to destroy them. They found that Capsaicin induces apoptosis (cell death) in cancer cells. When capsaicin reaches a cancer cell, it attaches to the cell surface and switches on a cell receptor, a protein expressed/produced on the cell surface, called TRPV1. The receptor TRPV1 is a calcium/sodium channel that controls them go in and out of the cancer cell. When TRPV1 is switched on by capsaicin, the cancer cell is sent into overdrive and starts to self-destruct by induced apoptosis (programmed cell death). The researchers have found a significant reduction in cell proliferation after capsaicin stimulation was observed.This study was carried out by scientists from:
Read more here in the news, and the original scientific article, Expression and functionality of TRPV1 in breast cancer cells, here.
University College London Hospitals (UCLH) researchers used a light-sensitive drug, which is injected into the bloodstream. A laser then activates the drug, which eradicates tumor tissue in the prostate. This new treatment is called vascular-targeted photodynamic therapy, or VTP.
Published in The Lancet Oncology, the study showed that 49 percent of patients given VTP went into ‘complete remission’ compared with 13.5 percent of patients in the control group.
The scientific title of the study is called 'Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial'
Read more on CNBC's website:
Read the scientific article on The Lancet Oncology's website:
FDA approves today Rubraca (rucaparib) to treat women with advanced ovarian cancer that has BRCA gene mutation.
BRCA genes are involved with repairing damaged DNA. Thus, under normal conditions, they work to prevent tumor development. However, mutations (abnormalities) of these genes may lead to certain cancers, which include breast and ovarian cancers. Rubraca is a poly ADP-ribose polymerase (PARP) inhibitor that blocks an enzyme (a protein involved in catalytic reactions in our body), which is involved in repairing damaged DNA. By blocking this enzyme through Rubraca, DNA inside the cancerous cells with damaged/mutated/abnormal BRCA genes may be less likely to be repaired by the enzyme, which leads to cell death and potentially a slow-down or inhibition of tumor growth.
Common side effects of Rubraca include nausea, fatigue, vomiting, low levels of red blood cells (anemia), abdominal pain, unusual taste sensation (dysgeusia), constipation, decreased appetite, diarrhea, low levels of blood platelets (thrombocytopenia) and trouble breathing (dyspnea). Rubraca is associated with serious risks, such as bone marrow problems (myelodysplastic syndrome), a type of cancer of the blood called acute myeloid leukemia and fetal harm.
Rubraca is marketed by Clovis Oncology, Inc. based in Boulder, Colorado. The FoundationFocus CDxBRCA companion diagnostic is marketed by Foundation Medicine, Inc. of Cambridge, Massachusetts.
For more information visit the FDA's website: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm533873.htm
President Obama signs #CuresAct bill, allocating $1.8 billion in cancer research - our cancer researcher CEO and Founder's thoughts
Today, President Barak Obama signed the 21st Century Cures Act in the White House. This $6.3 billion bill will fund drug treatment, a precision medicine initiative and Vice President Biden's #CancerMoonshot, efforts to end cancer.
Here are the thoughts of our brain cancer and cancer immunotherapy researcher, CEO and Founder, Dr. Sahin: "We at Cancer Education and Research Institute (CERI) are very pleased to hear that such a bill has been finally approved. As a cancer researcher, for years, we have been waiting for more funds to be allocated for cancer research, diagnostic, treatment, and prevention. Particularly as a brain cancer researcher, I can say that the allocation of cancer research funds by the NIH has been less equal among cancer types. Funding has been tight and more and more cancer research positions had been depending on it. Although I am now very excited to see that such a large sum of funding has been allocated for cancer research, yet, it was somewhat sad to see the realization that more funding for cancer research was dramatically needed only after the death of Vice President Joe Biden's son from brain cancer. I, personally, as a cancer researcher, would have wanted to see that our voices would have been heard much, much earlier and perhaps many more cancer patients could have been alive by now. And now, as an executive director and founder of a Boston-based, global cancer education nonprofit, I would to like push forward, once again, the importance of 'cancer patient education' as well as 'public education' about cancer. From our award-winning nonprofit's work worldwide, we have seen that cancer is truly a 'global' issue, and with no education on patients' end, an effective cancer treatment and in a timely fashion, will not be fully achieved. Patient education is the key for a complete 'teamwork' of the medical team to treat patients in a targeted and effective way. Our worldwide campaign, #empowermentagainstcancer, shows that people support cancer patients' education, want patients to be involved in their treatments, and thus, feeling empowered against their disease. We need to have patients to be involved in their treatments, decisions, and options, and for this, cancer education is a must. We at Cancer Education and Research Institute (CERI) look forward to the support in funding for cancer education, not only for cancer patients, but also for the general public for cancer prevention, including youth programs for children, like out CERI Youth Program, for development of healthier generations worldwide."
The bill also authorized seven years of funding for other health-related initiatives: $1.5 billion for a brain research initiative, $1.4 billion for precision medicine, and $1 billion for substance abuse treatment targeting heroin and opioid addiction.
Read more about the bill in the news here:
#CuresAct #CancerMoonshot #Cancer #cancereducation #patienteducation #publiceducation #canceredinstitute
Once oxidized vitamin C is taken up by the receptors and enters inside the cell, it kicked off a reaction that led to cell death (apoptosis) by depleting a molecule called glutathione, which normally binds to damaging free radicals and make them inactive.
The researcheres suggest that with more research, vitamin C could be used to treat some colon cancers.
NOTE: It is NOT suggested cancer patients under chemotherapy to consume grapefruit!
November 29 is #GivingTuesday!
Give today to help us truly save lives of people around the globe with your tax deductible donations!
Give Today. Donate Now. Click here to donate.
For immediate release: CANCER EDUCATION AND RESEARCH INSTITUTE (CERI) HONORED AS ‘2016 TOP-RATED NONPROFIT’ by GreatNonprofits